Oscar Health, Inc. (NYSE:OSCR - Get Free Report) has received an average recommendation of "Hold" from the nine ratings firms that are currently covering the stock, MarketBeat reports. Two analysts have rated the stock with a sell rating, two have assigned a hold rating, four have issued a buy rating and one has issued a strong buy rating on the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $21.56.
A number of equities analysts recently issued reports on OSCR shares. UBS Group started coverage on Oscar Health in a research note on Monday, October 7th. They issued a "neutral" rating and a $23.00 target price for the company. Bank of America lowered Oscar Health from a "neutral" rating to an "underperform" rating and reduced their target price for the stock from $21.00 to $13.50 in a research note on Wednesday, November 6th. Jefferies Financial Group started coverage on Oscar Health in a research note on Tuesday, December 10th. They issued an "underperform" rating and a $12.00 target price for the company. Finally, Piper Sandler restated an "overweight" rating and issued a $28.00 target price on shares of Oscar Health in a research note on Tuesday, September 10th.
Check Out Our Latest Stock Report on OSCR
In other Oscar Health news, Director Thrive Partners Vii Growth Gp, bought 420,819 shares of the company's stock in a transaction dated Tuesday, November 12th. The shares were purchased at an average cost of $13.68 per share, for a total transaction of $5,756,803.92. Following the transaction, the director now directly owns 5,452,081 shares of the company's stock, valued at approximately $74,584,468.08. The trade was a 8.36 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Vice Chairman Joshua Kushner bought 358,619 shares of the company's stock in a transaction dated Wednesday, November 13th. The shares were acquired at an average price of $13.74 per share, for a total transaction of $4,927,425.06. Following the completion of the transaction, the insider now directly owns 5,810,700 shares in the company, valued at approximately $79,839,018. This trade represents a 6.58 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last quarter, insiders purchased 1,055,478 shares of company stock worth $14,432,852 and sold 103,610 shares worth $1,847,519. Company insiders own 25.11% of the company's stock.
A number of institutional investors have recently modified their holdings of OSCR. Point72 Hong Kong Ltd acquired a new stake in shares of Oscar Health during the 2nd quarter valued at about $78,000. Quest Partners LLC acquired a new stake in Oscar Health in the 2nd quarter worth about $93,000. KBC Group NV boosted its holdings in Oscar Health by 41.2% in the 3rd quarter. KBC Group NV now owns 4,552 shares of the company's stock worth $97,000 after buying an additional 1,328 shares during the last quarter. Amalgamated Bank boosted its holdings in Oscar Health by 27.7% in the 2nd quarter. Amalgamated Bank now owns 6,727 shares of the company's stock worth $106,000 after buying an additional 1,458 shares during the last quarter. Finally, Optimum Investment Advisors acquired a new stake in Oscar Health in the 3rd quarter worth about $142,000. 75.70% of the stock is currently owned by institutional investors and hedge funds.
Shares of OSCR opened at $13.50 on Wednesday. Oscar Health has a 12 month low of $7.67 and a 12 month high of $23.79. The stock has a fifty day moving average price of $16.14 and a 200-day moving average price of $17.51. The company has a current ratio of 0.73, a quick ratio of 0.73 and a debt-to-equity ratio of 0.26. The firm has a market cap of $3.34 billion, a PE ratio of -225.00 and a beta of 1.63.
Oscar Health (NYSE:OSCR - Get Free Report) last issued its quarterly earnings data on Thursday, November 7th. The company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.02). Oscar Health had a net margin of 0.35% and a return on equity of 2.79%. The business had revenue of $2.42 billion for the quarter, compared to analysts' expectations of $2.33 billion. During the same quarter in the prior year, the company posted ($0.29) EPS. The business's revenue for the quarter was up 68.3% on a year-over-year basis. Equities research analysts predict that Oscar Health will post -0.01 earnings per share for the current fiscal year.
Oscar Health, Inc operates as a health insurance in the United States. The company offers health plans in individual and small group markets, as well as +Oscar, a technology driven platform that help providers and payors directly enable their shift to value-based care. It also provides reinsurance products.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Oscar Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oscar Health wasn't on the list.
While Oscar Health currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.